BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13:391-399. [PMID: 17318865 DOI: 10.1002/lt.21095] [Cited by in Crossref: 142] [Cited by in F6Publishing: 119] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Fischer SE. Recurrent and de novo malignancies following liver transplantation. Diagnostic Histopathology 2012;18:290-6. [DOI: 10.1016/j.mpdhp.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Reference Citation Analysis]
3 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
4 Said A, Lucey MR. Liver transplantation: an update 2008. Curr Opin Gastroenterol. 2008;24:339-345. [PMID: 18408462 DOI: 10.1097/mog.0b013e3282f8e27e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
5 Muscari F, Foppa B, Kamar N, Peron JM, Selves J, Suc B. Liberal selection criteria for liver transplantation for hepatocellular carcinoma. British Journal of Surgery 2009;96:785-91. [DOI: 10.1002/bjs.6619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, Park SJ. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant. 2016;6:411-422. [PMID: 27358787 DOI: 10.5500/wjt.v6.i2.411] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
7 Andersen MH, Dueland S, Hagness M, Vidnes T, Finstad ED, Wahl AK, Foss A. Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scand J Caring Sci. 2012;26:713-719. [PMID: 22452269 DOI: 10.1111/j.1471-6712.2012.00984.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lo C. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion. Am J Transplant. 2008;8:2485-2486. [PMID: 19032218 DOI: 10.1111/j.1600-6143.2008.02466.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
10 Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-537. [PMID: 19307789 DOI: 10.1097/tp.0b013e3181943bee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
11 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 188] [Article Influence: 40.3] [Reference Citation Analysis]
12 Vidnes TK, Wahl AK, Andersen MH. Patient experiences following liver transplantation due to liver metastases from colorectal cancer. European Journal of Oncology Nursing 2013;17:269-74. [DOI: 10.1016/j.ejon.2012.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
14 Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008;14:1449-1460. [PMID: 18825681 DOI: 10.1002/lt.21576] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
15 Fan J, Yang G, Fu Z, Peng Z, Xia Q, Peng C, Qian J, Zhou J, Xu Y, Qiu S, Zhong L, Zhou G, Zhang J. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009;135:1403-12. [DOI: 10.1007/s00432-009-0584-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
16 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
17 Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, Chung D, Park G, Yu Y, Choi N, Kim K, Kim K, Hwang S. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci. 2010;17:539-547. [PMID: 19727542 DOI: 10.1007/s00534-009-0167-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
18 Mazzotta AD, Pascale A, Cano L, Rosmorduc O, Allard MA, Sa Cunha A, Adam R, Cherqui D, Vibert E, Golse N. Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha-fetoprotein score: a new prognostic risk factor. Transpl Int 2021;34:954-63. [PMID: 33660346 DOI: 10.1111/tri.13858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 36.5] [Reference Citation Analysis]
20 Earl TM, Chapman WC. Transplantation for hepatocellular carcinoma: the North American experience. Recent Results Cancer Res 2013;190:145-64. [PMID: 22941019 DOI: 10.1007/978-3-642-16037-0_10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
21 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
22 Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci. 2010;17:443-448. [PMID: 19885638 DOI: 10.1007/s00534-009-0241-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
23 Vitale A, Cucchetti A, Qiao GL, Cescon M, Li J, Ramirez Morales R, Frigo AC, Xia Y, Tuci F, Shen F, Cillo U, Pinna AD. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. J Hepatol. 2014;60:1165-1171. [PMID: 24508550 DOI: 10.1016/j.jhep.2014.01.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
24 Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant. 2012;26:E125-E131. [PMID: 22192083 DOI: 10.1111/j.1399-0012.2011.01572.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
25 Liu F, Wei Y, Wang W, Chen K, Yan L, Wen T, Zhao J, Xu M, Li B. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLoS One. 2012;7:e48932. [PMID: 23145027 DOI: 10.1371/journal.pone.0048932] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
26 Zaydfudim VM, Vachharajani N, Klintmalm GB, Jarnagin WR, Hemming AW, Doyle MB, Cavaness KM, Chapman WC, Nagorney DM. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016;264:650-8. [PMID: 27433910 DOI: 10.1097/SLA.0000000000001866] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
27 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
28 Saberi B, Garonzik-Wang J, Ma M, Ajayi T, Kim A, Luu H, Jakhete N, Pustavoitau A, Anders RA, Georgiades C, Kamel I, Ottmann S, Philosophe B, Cameron AM, Gurakar A. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2020;18:463-9. [PMID: 30084757 DOI: 10.6002/ect.2017.0288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Klintmalm GB. Primum non nocere. Am J Transplant 2008;8:275-6. [PMID: 18211504 DOI: 10.1111/j.1600-6143.2007.02055.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Bhardwaj N, Perera MT, Silva MA. Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant 2016;2016:7926264. [PMID: 27413539 DOI: 10.1155/2016/7926264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
31 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012;3:49-61. [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36. [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
33 Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanus G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010;42:642-9. [PMID: 20381438 DOI: 10.1016/j.dld.2010.02.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
34 Elshamy M, Aucejo F, Menon KV, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016;8:874-80. [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
35 Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 380] [Article Influence: 48.7] [Reference Citation Analysis]
36 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 78] [Article Influence: 9.2] [Reference Citation Analysis]
37 Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362-2371. [PMID: 19656125 DOI: 10.1111/j.1600-6143.2009.02783.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 8.6] [Reference Citation Analysis]
38 Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-9. [PMID: 18408459 DOI: 10.1097/MOG.0b013e3282fafef3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
39 Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the α-fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population. Transplantation 2018;102:1316-22. [PMID: 29470357 DOI: 10.1097/TP.0000000000002136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
40 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016;8:881-90. [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
41 Wong L, Bozhilov K, Hernandez B, Kwee S, Chan O, Ellis L, LeMarchand L. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio. Clin Mol Hepatol. 2019;25:305-316. [PMID: 31001964 DOI: 10.3350/cmh.2019.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
42 Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Román A, Serón D, Ussetti P; ATOS Working Group. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 2012;26:261-79. [PMID: 22902168 DOI: 10.1016/j.trre.2012.07.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
43 Canter RJ, Patel SA, Kennedy T, D'Angelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, DeMatteo RP, Abt PL. Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the milan criteria treated with liver transplantation versus partial hepatectomy. Am J Clin Oncol 2011;34:466-71. [PMID: 20938319 DOI: 10.1097/COC.0b013e3181ec63dd] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
45 Foss A, Adam R, Dueland S. Liver transplantation for colorectal liver metastases: revisiting the concept. Transpl Int. 2010;23:679-685. [PMID: 20477993 DOI: 10.1111/j.1432-2277.2010.01097.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
46 Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl. 2009;15:1861-1866. [PMID: 19938113 DOI: 10.1002/lt.21940] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
47 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
48 Nagano Y, Shimada H, Takeda K, Ueda M, Matsuo K, Tanaka K, Endo I, Kunisaki C, Togo S. Predictive factors of microvascular invasion in patients with hepatocellular carcinoma larger than 5 cm. World J Surg 2008;32:2218-22. [PMID: 18642045 DOI: 10.1007/s00268-008-9585-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
49 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Kim JM, Kwon CH, Joh JW, Kim SJ, Shin M, Kim EY, Moon JI, Jung GO, Choi GS, Lee SK. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? Transplant Proc 2010;42:821-4. [PMID: 20430181 DOI: 10.1016/j.transproceed.2010.02.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
51 Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando). 2010;24:11-17. [PMID: 19942101 DOI: 10.1016/j.trre.2009.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
52 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17 Suppl 2:S81-S89. [PMID: 21748847 DOI: 10.1002/lt.22380] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
54 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 10.4] [Reference Citation Analysis]
55 Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc. 2008;40:3548-3553. [PMID: 19100435 DOI: 10.1016/j.transproceed.2008.03.165] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
56 Kashkoush S, El Moghazy W, Kawahara T, Gala-lopez B, Toso C, Kneteman NM. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant 2014;28:728-36. [DOI: 10.1111/ctr.12373] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
57 Denecke T, Grieser C, Fröling V, Steffen IG, Rudolph B, Stelter L, Lehmkuhl L, Streitparth F, Langrehr J, Neuhaus P. Multislice computed tomography using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation. Transpl Int. 2009;22:395-402. [PMID: 19000231 DOI: 10.1111/j.1432-2277.2008.00793.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
58 Weber M, Clavien P. Hepatocellular carcinoma and liver transplantation: Entering the area after the Milan and University of California at San Francisco criteria? Liver Transpl 2008;14:911-4. [DOI: 10.1002/lt.21487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
59 Del Pozo AC, López P. Management of hepatocellular carcinoma. Clin Liver Dis. 2007;11:305-321. [PMID: 17606209 DOI: 10.1016/j.cld.2007.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
60 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
61 Kim PTW, Onaca N, Chinnakotla S, Davis GL, Jennings LW, Mckenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013;27:311-8. [DOI: 10.1111/ctr.12089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
62 Gunay Y, Guler N, Yaprak O, Dayangac M, Akyildiz M, Altaca G, Yuzer Y, Tokat Y. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg 2015;77:950-6. [PMID: 27011489 DOI: 10.1007/s12262-014-1078-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
63 Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am. 2010;18:421-450, x. [PMID: 21094448 DOI: 10.1016/j.mric.2010.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
64 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
65 Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869-75. [PMID: 19386075 DOI: 10.1111/j.1432-2277.2009.00882.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
66 Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
67 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 102] [Article Influence: 9.8] [Reference Citation Analysis]
68 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
69 Bo W, Yan L. The Difference and the Transition of Indication for Adult Living Donor Liver Transplantation Between the West and the East. Transplantation Proceedings 2008;40:3507-11. [DOI: 10.1016/j.transproceed.2008.06.096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation. Hepatology 2011;53:1570-9. [DOI: 10.1002/hep.24231] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
71 Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology. 2011;81 Suppl 1:111-115. [PMID: 22212944 DOI: 10.1159/000333270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
72 Hwang S, Moon D, Lee S. Liver transplantation and conventional surgery for advanced hepatocellular carcinoma: Liver transplantation and surgery. Transplant International 2010;23:723-7. [DOI: 10.1111/j.1432-2277.2010.01103.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
73 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Commander SJ, Shaw B, Washburn L, Yoeli D, Rana A, Goss JA. A long-term experience with expansion of Milan criteria for liver transplant recipients. Clin Transplant 2018;32:e13254. [DOI: 10.1111/ctr.13254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Tsoulfas G, Mekras A, Agorastou P, Kiskinis D. Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg. 2012;82:510-517. [PMID: 22548726 DOI: 10.1111/j.1445-2197.2012.06079.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
77 Pomfret EA, Lodge JP, Villamil FG, Siegler M. Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl. 2011;17 Suppl 2:S128-S132. [PMID: 21656657 DOI: 10.1002/lt.22356] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
78 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
79 Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, Sonzogni A, Colledan M, D’Antiga L. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant. 2011;15:573-579. [PMID: 21797955 DOI: 10.1111/j.1399-3046.2011.01528.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
80 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
81 Sposito C, Cucchetti A, Mazzaferro V. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. Dig Dis Sci 2019;64:1001-7. [DOI: 10.1007/s10620-019-05538-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
82 Emmanouilidis N, Peters R, Ringe BP, Güner Z, Ramackers W, Bektas H, Lehner F, Manns M, Klempnauer J, Schrem H. Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience. J Transplant 2016;2016:7895956. [PMID: 27057348 DOI: 10.1155/2016/7895956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
83 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
84 Guiteau JJ, Cotton RT, Washburn WK, Harper A, O’Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant. 2010;10:2092-2098. [PMID: 20883543 DOI: 10.1111/j.1600-6143.2010.03222.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
85 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
86 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
87 Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol 2015;11:2923-36. [PMID: 26414336 DOI: 10.2217/fon.15.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
88 Martin AP. Management of hepatocellular carcinoma in the age of liver transplantation. Int J Surg 2009;7:324-9. [PMID: 19643691 DOI: 10.1016/j.ijsu.2008.12.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013;:CD006935. [PMID: 23813393 DOI: 10.1002/14651858.CD006935.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
90 Harper AM, Edwards E, Washburn WK, Heimbach J. An early look at the Organ Procurement and Transplantation Network explant pathology form data: OPTN Explant Pathology Form Data. Liver Transpl 2016;22:757-64. [DOI: 10.1002/lt.24441] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
91 Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RS. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. Ann Surg. 2017;265:557-564. [PMID: 27611615 DOI: 10.1097/sla.0000000000001966] [Cited by in Crossref: 108] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
92 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
93 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
94 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
95 Varona MA, Del Pino JM, Barrera M, Arranz J, Hernández BM, Perez HF, Padilla J, Fuentes JS, Aguirre A, Mendez S. Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc. 2009;41:1005-1008. [PMID: 19376411 DOI: 10.1016/j.transproceed.2009.02.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
96 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
97 Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, Eghtesad B, Miller C, Fung J, Tan A. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2015;21:101-111. [PMID: 25283528 DOI: 10.1002/lt.24013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
98 Villacastín Ruiz E, Caro-Patón Gómez A, Calero Aguilar H, Pérez Saborido B, García Pajares F, Sánchez Antolín G, Madrigal Rubiales B, Pacheco Sánchez D, Pintado Garrido R, Plaza Loma S, Escudero Caro T. Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. Eur J Gastroenterol Hepatol 2016;28:412-20. [PMID: 26760587 DOI: 10.1097/MEG.0000000000000528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Xu X, Qu K, Wan Y, Song S, Huang Z, Wang Z, Liu C. Tumor Existence and Tumor Size as Prognostic Factors in Hepatitis B Virus–Related Cirrhosis Patients Who Underwent Liver Transplantation. Transplantation Proceedings 2014;46:1389-92. [DOI: 10.1016/j.transproceed.2014.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
100 Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. European Journal of Gastroenterology & Hepatology 2014;26:200-4. [DOI: 10.1097/meg.0b013e3283652b66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
101 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 95] [Article Influence: 23.6] [Reference Citation Analysis]
102 Decaens T, Hurtova M, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2009;33:61-9. [DOI: 10.1016/j.gcb.2008.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
104 Li W, Li L, Han J, Wu H. Liver transplantation vs liver resection in patients with HBV-related hepatocellular carcinoma beyond Milan criterion: A meta-analysis. Clin Transplant 2018;32:e13193. [PMID: 29315813 DOI: 10.1111/ctr.13193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Mullath A, Krishna M. Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg 2019;11:287-95. [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
107 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 229] [Article Influence: 24.4] [Reference Citation Analysis]
108 Balci D, Dayangac M, Yaprak O, Akin B, Duran C, Killi R, Yuzer Y, Tokat Y. Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria: Living donor liver transplantation for hepatocellular carcinoma. Transplant International 2011;24:1075-83. [DOI: 10.1111/j.1432-2277.2011.01311.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
109 Kim PT, Testa G. Living donor liver transplantation in the USA. Hepatobiliary Surg Nutr. 2016;5:133-140. [PMID: 27115007 DOI: 10.3978/j.issn.2304-3881.2015.06.01] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
110 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
111 Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14:935-945. [PMID: 18581465 DOI: 10.1002/lt.21445] [Cited by in Crossref: 206] [Cited by in F6Publishing: 183] [Article Influence: 15.8] [Reference Citation Analysis]
112 Hurtova M, Decaens T, Laurent A, Cherqui D, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire et chez les malades avec antécédents de cancer. La Presse Médicale 2009;38:1272-80. [DOI: 10.1016/j.lpm.2009.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
113 Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, Pawlik TM. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 2015;39:1474-1484. [PMID: 25665675 DOI: 10.1007/s00268-015-2987-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
114 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
115 Rosenthal P. Hepatocarcinoma in Viral and Metabolic Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2008;46:370-5. [DOI: 10.1097/mpg.0b013e318158799b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
116 Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria: Expanded Criteria for LT in HCC. Liver Transpl 2008;14:272-8. [DOI: 10.1002/lt.21368] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
117 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
118 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014;20:15007-17. [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
119 Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899-903. [PMID: 23769067 DOI: 10.1016/j.transproceed.2012.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]